Khurshid Shaan, Weng Lu-Chen, Hulme Olivia L, Ellinor Patrick T, Lubitz Steven A
Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts.
Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts.
Am J Cardiol. 2017 Oct 15;120(8):1316-1321. doi: 10.1016/j.amjcard.2017.07.017. Epub 2017 Jul 24.
Oral anticoagulation (OAC) is effective yet reportedly underutilized for stroke prevention in atrial fibrillation (AF). Factors associated with delayed OAC after incident AF are unknown. Using a large electronic medical record, we identified incident episodes of AF diagnosed in 2006 to 2014 using a validated algorithm. Among patients with a Congestive heart failure, Hypertension, Age, Diabetes, and Stroke (CHADS) score ≥1 started on OAC within 1 year, we examined baseline characteristics at AF diagnosis and their association with time to OAC using multivariable Cox proportional hazards modeling. Of 4,388 patients with incident AF and CHADS score ≥1 who were started on OAC within 1 year, the mean age was 72.6, and 41% were women. Median time to OAC was 5 days (interquartile range 1 to 43), and most patients received warfarin (86.3%). Among patients without prevalent stroke, 98 strokes (2.2% of the sample) occurred between AF diagnosis and OAC initiation. In multivariable analyses, several factors were associated with delayed OAC including female gender (hazard ratio [HR] 1.08, 95% confidence interval [CI] 1.01 to 1.15), absence of hypertension (HR 1.15, 95% CI 1.03 to 1.27), previous fall (HR 1.53, 95% CI 1.08 to 2.17), and chronic kidney disease (HR 1.12, 95% CI 1.04 to 1.21). Among women, OAC prescription at 1, 3, and 6 months was 70.0%, 81.7%, and 89.5%, respectively, whereas for men, OAC prescription was 73.4%, 84.0%, and 91.5%, respectively. Most patients with new AF and elevated stroke risk started on OAC receive it within 1 week, although the promptness of initiation varies. The stroke rate is substantial in the period between AF diagnosis and OAC initiation. Interventions targeting identified risk factors for delayed OAC may result in improved outcomes.
口服抗凝药(OAC)对预防心房颤动(AF)导致的中风有效,但据报道其使用率不足。AF发病后OAC延迟使用的相关因素尚不清楚。我们利用大型电子病历,通过验证算法识别出2006年至2014年诊断的AF发病事件。在1年内开始使用OAC且充血性心力衰竭、高血压、年龄、糖尿病和中风(CHADS)评分≥1的患者中,我们在AF诊断时检查了基线特征,并使用多变量Cox比例风险模型研究了这些特征与开始使用OAC时间的关联。在4388例1年内开始使用OAC的AF发病且CHADS评分≥1的患者中,平均年龄为72.6岁,41%为女性。开始使用OAC的中位时间为5天(四分位间距为1至43天),大多数患者接受华法林治疗(86.3%)。在无既往中风的患者中,98例中风(占样本的2.2%)发生在AF诊断至开始使用OAC之间。在多变量分析中,几个因素与OAC延迟使用有关,包括女性(风险比[HR]1.08,95%置信区间[CI]1.01至1.15)、无高血压(HR 1.15,95%CI 1.03至1.27)、既往跌倒(HR 1.53,95%CI 1.08至2.17)和慢性肾病(HR 1.12,95%CI 1.04至1.21)。在女性中,1个月、3个月和6个月时OAC处方率分别为70.0%、81.7%和89.5%,而男性分别为73.4%、84.0%和91.5%。大多数有新发AF且中风风险升高并开始使用OAC的患者在1周内接受了治疗,尽管开始治疗的及时性有所不同。在AF诊断至开始使用OAC期间中风发生率较高。针对已确定的OAC延迟使用风险因素进行干预可能会改善预后。